Ratings CMK Corporation

Equities

6958

JP3712000003

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-14 EDT			5-day change	1st Jan Change
625 ^JPY	+0.16%		+6.11%	-24.70%

02-28	Aurora Cannabis Teams Up With Script Assist to Provide Access to UK Medical Cannabis; Down 1.8%	MT
02-28	Aurora Cannabis Teams Up With Script Assist to Provide Access to UK Medical Cannabis	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.55 for the 2024 fiscal year.
The company's share price in relation to its net book value makes it look relatively cheap.
Over the last twelve months, the sales forecast has been frequently revised upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Semiconductors

	1st Jan change	Capi.	ESG Refinitiv
CMK CORPORATION	-24.70%	269M	-
MEDIATEK INC.	+9.85%	54.73B	B-
SKYWORKS SOLUTIONS, INC.	-16.47%	15.07B	B
NOVATEK MICROELECTRONICS CORP.	+13.54%	11.02B	B+
UNIMICRON TECHNOLOGY CORP.	+5.97%	8.76B	B
AVARY HOLDING(SHENZHEN)CO., LIMITED	+24.55%	8.88B	B-
WUS PRINTED CIRCUIT (KUNSHAN) CO., LTD.	+44.03%	8.43B	D+
UNIVERSAL DISPLAY CORPORATION	-9.56%	8.21B	B-
UNIGROUP GUOXIN MICROELECTRONICS CO., LTD.	-14.29%	6.74B	C-
GLOBALWAFERS CO., LTD.	-12.10%	6.94B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes